Memantine Hydrochloride
Product Images NDC 0904-6736

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 0904-6736). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (5e5af07b 40d8 4008 Ad29 630efd1831a5 01)

Chemical structure of memantine hydrochloride showing the molecular framework with an amine group and hydrochloride component.*

FDA Label Image

Figure 2 (5e5af07b 40d8 4008 Ad29 630efd1831a5 02)

A line graph depicting mean change from baseline in SIB (Severe Impairment Battery) score over 24 weeks of treatment comparing Memantine HCl Extended-Release 28 mg plus AChEI versus Placebo plus AChEI. The graph includes error bars showing SEM and indicates trends of clinical improvement versus decline over time for each group.*

FDA Label Image

Figure 3 (5e5af07b 40d8 4008 Ad29 630efd1831a5 03)

A cumulative percentage of patients plot showing SIB change from baseline on the x-axis and cumulative percentage on the y-axis. The graph compares Memantine HCl Extended-Release 28 mg/AChEI treatment (black circles) versus Placebo/AChEI (white circles), indicating patient response distributions.*

FDA Label Image

Figure 4 (5e5af07b 40d8 4008 Ad29 630efd1831a5 04)

A line graph depicting mean CBIC-Plus Score ± SEM versus weeks of treatment (0 to 24 weeks). Two groups are compared: Memantine HCl Extended-Release 28 mg and Placebo, measured over time. The graph highlights clinical improvement and decline thresholds indicated by a horizontal dashed line at score 4.0.*

FDA Label Image

Figure 5 (5e5af07b 40d8 4008 Ad29 630efd1831a5 05)

A bar chart comparing the percentage of patients showing different levels of clinical change based on the CIBIC Plus Rating. It contrasts patients treated with Memantine HCl Extended-Release 28 mg combined with AChEI versus a placebo combined with AChEI. Categories shown range from marked improvement to marked worsening.*

FDA Label Image

Carton Label (Image 01)

Label for memantine hydrochloride extended-release capsules by Major Pharmaceuticals, showing strengths of 7 mg and 28 mg per capsule. The label states the capsules are unit dose, taken once daily, and available in a package of 100 capsules. It includes usage instructions, storage conditions, and distributor information.*

FDA Label Image

Carton Label (Image 02)

Memantine hydrochloride 14 mg extended-release capsules packaging label by Major Pharmaceuticals. The label indicates unit dose, once-daily administration, and contains 100 capsules. Instructions advise pharmacist to dispense with patient information leaflet and storage conditions are specified.*

FDA Label Image

Image 03

Memantine hydrochloride 21 mg extended-release capsules unit dose labeling by Major Pharmaceuticals. The label shows the NDC 0904-6737-61 and states once-daily dosing. It includes patient information instructions, storage conditions, and usage warnings, specifying dispensing with a patient information leaflet and limiting use to institutional settings. The label also indicates the product contains 100 capsules per package.*

FDA Label Image

Image 04

Packaging label for memantine hydrochloride extended-release capsules by Major Pharmaceuticals, showing strengths of 28 mg and 7 mg. The label includes NDC codes 0904-6735-61 and 0904-6735-61, dosage form as unit dose once-daily capsules, quantity of 100 capsules, and instructions for pharmacists to dispense with a patient information leaflet. Storage and handling details and manufacturer information are also present.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.